Martha O. Correa-Posada, John F. García-Velez, Orestes André Hurtado-Mosquera, M. A. Sierra-Juárez, Erick Fernando Hernández, Cinthia N. Argüelles Castillo, German E. Mendoza Barrera, A. I. Valderrama-Treviño
{"title":"血栓闭塞性脉管炎:综述","authors":"Martha O. Correa-Posada, John F. García-Velez, Orestes André Hurtado-Mosquera, M. A. Sierra-Juárez, Erick Fernando Hernández, Cinthia N. Argüelles Castillo, German E. Mendoza Barrera, A. I. Valderrama-Treviño","doi":"10.18203/2349-2902.isj20241283","DOIUrl":null,"url":null,"abstract":"Buerger's disease was initially described by von Winiwarter in 1879 where he described it as thromboangiitis obliterans (TAO), detailing the case of spontaneous gangrene secondary to intimal proliferation. In 1908, Leo Buerger published a complete pathological description based on the amputation of a group of people who later suffered short-term gangrene. Buerger's disease or TAO is defined as a non-atherosclerotic inflammatory vasculitis that affects the small and medium vessels (including arteries and veins) of the lower and upper extremities. Although there are hypotheses about its etiopathogenesis such as the association with exposure to tobacco, few biomedical investigations have been carried out, so its direct causality remains unknown. Diagnosis continues to be a challenge, since the findings tend to be non-specific or inconsistent with suspicion, which is why it is currently based on ruling out other causes such as atherosclerosis and vasculopathies. With current evidence, there are many types of treatments, both pharmacological and non-pharmacological, with the cessation of tobacco consumption having greater evidence of results. It is essential to strengthen basic research as well as clinical trials to standardize management in this type of patient, since it is a disease with a high impact on quality of life.\n ","PeriodicalId":14372,"journal":{"name":"International Surgery Journal","volume":"43 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Thromboangiitis obliterans: a review\",\"authors\":\"Martha O. Correa-Posada, John F. García-Velez, Orestes André Hurtado-Mosquera, M. A. Sierra-Juárez, Erick Fernando Hernández, Cinthia N. Argüelles Castillo, German E. Mendoza Barrera, A. I. Valderrama-Treviño\",\"doi\":\"10.18203/2349-2902.isj20241283\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Buerger's disease was initially described by von Winiwarter in 1879 where he described it as thromboangiitis obliterans (TAO), detailing the case of spontaneous gangrene secondary to intimal proliferation. In 1908, Leo Buerger published a complete pathological description based on the amputation of a group of people who later suffered short-term gangrene. Buerger's disease or TAO is defined as a non-atherosclerotic inflammatory vasculitis that affects the small and medium vessels (including arteries and veins) of the lower and upper extremities. Although there are hypotheses about its etiopathogenesis such as the association with exposure to tobacco, few biomedical investigations have been carried out, so its direct causality remains unknown. Diagnosis continues to be a challenge, since the findings tend to be non-specific or inconsistent with suspicion, which is why it is currently based on ruling out other causes such as atherosclerosis and vasculopathies. With current evidence, there are many types of treatments, both pharmacological and non-pharmacological, with the cessation of tobacco consumption having greater evidence of results. It is essential to strengthen basic research as well as clinical trials to standardize management in this type of patient, since it is a disease with a high impact on quality of life.\\n \",\"PeriodicalId\":14372,\"journal\":{\"name\":\"International Surgery Journal\",\"volume\":\"43 5\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Surgery Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18203/2349-2902.isj20241283\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Surgery Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2349-2902.isj20241283","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Buerger 病最初是由 von Winiwarter 于 1879 年描述的,他将其描述为血栓闭塞性脉管炎(TAO),详细描述了继发于内膜增生的自发性坏疽病例。1908 年,利奥-比尔格(Leo Buerger)发表了一份完整的病理描述,其依据是对一组后来患有短期坏疽的人的截肢手术。Buerger 病或 TAO 被定义为一种非动脉粥样硬化性炎症性血管炎,会影响下肢和上肢的中小血管(包括动脉和静脉)。虽然有一些关于其发病机制的假设,如与接触烟草有关,但很少进行生物医学研究,因此其直接因果关系仍然未知。诊断仍然是一项挑战,因为诊断结果往往是非特异性的或与怀疑不一致,这就是为什么目前诊断的基础是排除其他病因,如动脉粥样硬化和血管疾病。根据目前的证据,治疗方法有很多种,包括药物治疗和非药物治疗,其中戒烟的效果证据更多。必须加强基础研究和临床试验,以规范这类患者的治疗,因为这种疾病对生活质量的影响很大。
Buerger's disease was initially described by von Winiwarter in 1879 where he described it as thromboangiitis obliterans (TAO), detailing the case of spontaneous gangrene secondary to intimal proliferation. In 1908, Leo Buerger published a complete pathological description based on the amputation of a group of people who later suffered short-term gangrene. Buerger's disease or TAO is defined as a non-atherosclerotic inflammatory vasculitis that affects the small and medium vessels (including arteries and veins) of the lower and upper extremities. Although there are hypotheses about its etiopathogenesis such as the association with exposure to tobacco, few biomedical investigations have been carried out, so its direct causality remains unknown. Diagnosis continues to be a challenge, since the findings tend to be non-specific or inconsistent with suspicion, which is why it is currently based on ruling out other causes such as atherosclerosis and vasculopathies. With current evidence, there are many types of treatments, both pharmacological and non-pharmacological, with the cessation of tobacco consumption having greater evidence of results. It is essential to strengthen basic research as well as clinical trials to standardize management in this type of patient, since it is a disease with a high impact on quality of life.